Sydbank: A positive signal
Sydbank analyst, Søren Løntoft Hansen, is up-beat about the expected, European sales-level of Lundbeck’s new pill for alcohol addiction, albeit less so than the company itself.
by Henrik Tüchsen
EU approval of the Danish company’s alcohol-pill, Selincro, would send a great signal, as the company would gain be gaining approval for drugs that can help it traverse an impending patent cliff, says Sydbank’s stock market analyst and pharmaceutical expert, Søren Løntoft Hansen. But he is not quite as positive as Lundbeck when it comes to expectations for annual European sales.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
